The Shkreli Pill

• Treat KOD only as a high-risk, short-term rebound trade: the discussion cites below $30 as a possible entry and below $25 as more attractive, but warns selling may continue and questions the drug’s clinical advantage and insurance coverage.
• Avoid treating those levels as validated price targets or a long-term buy case; ITCI is mentioned only as an example that a drug can succeed in a crowded market, not as a recommendation.
• Trade options cautiously: understand the strike, expiration, and delta, since inexpensive out-of-the-money calls can expire worthless.
• Evaluate any future OpenAI or other AI-company IPO on its own valuation and fundamentals; no specific listing or investment recommendation is provided.

• Intel (INTC) is the clearest bullish stock view: the speaker is long, but gave no price target or timeframe, so treat it as a limited-conviction idea.
• Watch upcoming results and spending guidance from Alphabet, Microsoft, Apple, and Amazon for signals about memory demand affecting SanDisk (SNDK), Micron (MU), and SK hynix; no confirmed catalyst was established.
• For simpler exposure, consider whether SMH (semiconductors) or SPY (the broad market) better matches your goals rather than holding several overlapping stock positions.
• Preserve capital: keep new positions small, avoid adding to losers or using leveraged ETFs, and don’t force trades while in a drawdown.

• Consider SMH as a hedge for concentrated semiconductor longs, since it was described as highly correlated with the broader market; size any hedge carefully, as it may not offset company-specific losses.
• The clearest bearish ideas were IONQ, QBTS, and RGTI, but these volatile short candidates came with no price targets or catalysts, so research and risk limits are essential.
• LRCX, ADI, and ALAB were also floated as potential semiconductor shorts against long holdings, without supporting valuation analysis.
• MRNA was called a short-term short opportunity around $213–$215, but this was a trading view without a stated target or timeframe.

Avoid shorting Twist Bioscience (TWST) solely because it looks expensive: the business is growing rapidly, though no buy target or timing was provided.
The speaker remains short Moderna (MRNA) at around $210, but offered no thesis, target, or timeframe, so this is not a well-supported trade to follow.
Do not add to Nektar Therapeutics (NKTR) based on these insights; the speaker is down about 50% and did not recommend buying more.

• Treat Liquidia (LQDA)’s reported court stipulation as an uncertain catalyst: wait for the sealed terms or company disclosure before acting; the reported $28 share price is not a target.
• Abivax (ABVX) was the clearest long-term bullish mention, but no price target or catalyst was given, and the speaker stressed that investors should be patient.
• Consider Wolfspeed (WOLF) or Rigetti (RGTI) only as leads for further short research; the discussion offered no valuation, timing, or developed thesis, and shorting carries substantial risk.
• Avoid trading on the unverified AMD (AMD) customer claims or rumors; size positions conservatively and understand the thesis before investing.

• Consider a bearish position in Recursion Pharmaceuticals (RXRX) only if comfortable with high risk; the discussion flags uncertain pipeline value, substantial cash burn, and possible dilution as key concerns.
• Twist Bioscience (TWST) may offer growth exposure, but the speaker viewed its roughly $10 billion valuation as difficult to justify before stronger margins and profitability emerge.
• Liquidia (LQDA) received a bullish personal endorsement, but no price target, catalyst, or supporting thesis was provided, so further research is needed before acting.
• Avoid trading ASML on unverified claims about upcoming results; rely on public disclosures rather than potentially material nonpublic information.

• Avoid Martingale-style doubling down; repeated increases after losses can magnify risk and potentially wipe out your capital.
• Treat bearish comments on DNA, SLS, RXRX, MRNA, and WOLF as unverified views, not automatic short signals; no price targets or clear timing were provided, and shorting volatile stocks can lead to severe losses.
• For biotech investments, prioritize companies with credible clinical evidence, a viable path to FDA approval, and sufficient funding rather than relying on speculative drug claims.
• Build trading discipline by keeping a trade journal, reviewing past trades, and researching companies before taking a position.

• STX: Hold or add cautiously only after verifying the disputed Toshiba deal reports; speakers saw the dip as a possible opportunity but acknowledged losses and short-term uncertainty.
• ASML: Avoid acting on the unverified claim of a potential 40% drop; check the company’s guidance and export-control updates before taking a position.
• INTC: Treat earnings on the 29th as the key near-term catalyst; the discussion noted recent weakness but offered no clear earnings outlook.
• DNA, RXRX, and TWST: Be cautious about AI-biotech enthusiasm without evidence of drug-development progress; the cited downside views were opinions, not confirmed targets.

• KLIC is a high-risk, cyclical recovery play: consider it only if you believe advanced-packaging and data-center demand can offset weakness in legacy products; its backlog is cancelable and not guaranteed revenue.
• The speaker floated a possible KLIC move to $140–$150, but gave no timeframe, and valuation depends on uncertain growth and margin assumptions.
• Treat potential business with Micron, SanDisk, Intel, and TSMC as unconfirmed; avoid basing a trade on those customer speculations.
• The discussion does not provide enough evidence for actionable positions in MRNA, UMC, STX, or quantum-computing stocks; avoid leveraged trades without a clear thesis and liquidation plan.

• Micron (MU): Monitor the union vote scheduled for the 22nd; labor negotiations and a possible strike could drive volatility, but the discussion offers no firm directional call.
• Kulicke & Soffa (KLIC): Research its sharp revenue and profit growth, while checking whether recent results are sustainable and assessing its planned exit from the EA equipment business before considering a position.
• Treat the Tesla–TSMC contract speculation and PTC takeover approach as unconfirmed; verify official updates before trading.
• The commentary did not establish a high-conviction trade or reliable price target for the other stocks mentioned.

• Treat sharp moves in SanDisk (SNDK), Micron (MU), Taiwan Semiconductor (TSM), and Agenus (AGEN) cautiously: hedge-fund deleveraging or short covering may drive volatility without company-specific news.
• Avoid sizing short positions too aggressively in volatile stocks like AGEN or Moderna (MRNA), where sudden rallies can make losses difficult to manage.
• Before investing in companies with complex warrants or preferred stock, assess potential dilution to common shareholders; the concerns described for QCLS warrant particular caution.
• Use caution with leveraged Bitcoin (BTC) trades and understand platform-specific margin and liquidation rules before opening a position.
• Consider private-equity buyouts only if you can tolerate illiquidity and a multi-year holding period; no specific price targets or near-term buy recommendations are provided.

• The discussion offers no high-conviction current buy: Liquidia (LQDA) is cited as a past winner, but its sharp volatility and conflicting trade histories make it unsuitable as a fresh recommendation without current research.
• Treat Nektar Therapeutics (NKTR) cautiously; the speaker raised concerns about its drug approach and competition, but provided no price target or timeline.
• Seagate (STX) and SanDisk (SNDK) face uncertainty after Toshiba’s capacity announcement, so avoid treating the speakers’ long positions as a clear signal to buy.
• The claims of 1%–2% daily returns from automated trading are anecdotal and lack a verified track record; don’t rely on them as an investment strategy.

• Consider Liquidia (LQDA) only as a high-risk, event-driven idea: the speaker sees potential for a return to $100 if it wins its appeal, but that outcome is uncertain.
• The clearest bearish theme is semiconductor supply risk: the speaker was short Micron (MU) and ASML, and flagged SanDisk as vulnerable if Asian supply rises; no price targets were provided.
• The speaker also favored shorting technology over healthcare, citing potential supply pressure and CPU weakness that could affect Dell (DELL), Intel (INTC), and AMD (AMD), though this was a developing thesis rather than a defined trade.
• MongoDB (MDB) was a tentative hold, with a possible re-entry below $351; the speaker expressed hesitation about software stocks and did not favor a larger position.

• Treat LQDA only as a high-risk rebound trade, not a long-term investment: consider staged entries below $30, with $25 cited as a more attractive level, and be prepared for further losses; a bounce toward $35 was speculative.
• The court ruling favors UTHR relative to LQDA, so UTHR may serve as a hedge against LQDA exposure, though no price target was provided.
• For MDB, the discussed $350/$400 call spread can cap both cost and upside, but no expiration or final recommendation was given; avoid selling $340 puts unless prepared to buy shares if the stock falls.

• MongoDB (MDB) is the clearest near-term bullish setup: the speaker saw potential for a move from around $350 to $400 within about a week, though this is speculative and not guaranteed.
• Moderna (MRNA) may offer a short-term momentum rebound after falling about 7% on a Citi downgrade, but no price target or holding period was provided.
• Ginkgo Bioworks (DNA) was flagged as a possible short, but the lack of a supporting thesis or target makes it a high-risk idea to investigate rather than act on directly.

• Consider Bloom Energy (BE) as a way to gain exposure to rising data-center power demand, but verify its ability to build projects at scale amid construction and regulatory hurdles.
• Treat Kodiak Sciences (KOD) as a high-risk, crowded short rather than an actionable bearish trade: the speaker remains skeptical of its drug evidence, but acknowledged that potential $200–$600 million revenue and high short interest could drive further gains.
• Avoid trading Iovance (IOVA) solely on the mixed momentum comments; the stock was described as both likely to climb and overextended, with no price target or clear timeframe.

• MDB is the clearest short-term trade: the speaker expected it to reach $340 intraday after discussing entries around $325; treat this as a trading target, not a long-term valuation.
• QURE remains a cautious bullish watch, but consider re-entering only on a pullback given regulatory-review volatility; no new entry price was specified.
• Avoid chasing IOVA after its sharp rally from about $8 to $13: raised guidance supports the bullish case, but the stock may retrace.
• KOD has a bearish valuation view of $50–$60 or less versus roughly $85, but its rising price and squeeze risk make shorting especially hazardous.

• Wait for Micron (MU)’s upcoming results and company commentary to confirm whether semiconductor demand is weakening; avoid shorting MU or SanDisk (SNDK) before the evidence is clearer.
• Treat the proposed short in AMD as high risk: the bearish case hinges on its ability to compete with NVIDIA, while strong momentum could drive further gains.
• Meta (META)’s AI investment may prove strategically valuable, but the discussion offered no price target—watch for evidence of durable business results before acting.

• The clearest relative-value idea is long Sandisk (SNDK) / short Intel (INTC), based on the view that AI demand supports memory more than Intel; the pair can still lose if either stock moves sharply.
• Kodiak Sciences (KOD) was flagged as a high-risk, event-driven short ahead of Monday’s clinical results, but a positive surprise could trigger a sharp rally—avoid oversized positions.
• AMD has strong momentum but may be due for a pause; the discussion provides no price target or firm entry point, so avoid chasing the recent run.
• Treat all trade views as time-sensitive, especially shorts, and size positions to withstand sudden adverse moves.

• Avoid chasing AMD at an elevated valuation; its AI-driven CPU-demand upside is uncertain, and strong momentum and supply-constrained demand make a short risky—if already short, consider reducing the position rather than adding.
• Treat the reported contract issue behind Oracle’s 5%–7% drop as a near-term catalyst to monitor, not a buy or sell signal; the financial impact and resolution are unclear.
• Be cautious on semiconductor stocks broadly: rising manufacturing output may signal cycle risk, and the discussion offered no clear sector-wide buy.
• Wait for more information before considering Anthropic’s IPO; the speaker would not buy without knowing the offering price.